An Innovative Approach to Combating Hepatitis C in Michigan
In 2024, Egypt achieved a remarkable milestone by becoming the first country to eliminate chronic hepatitis C as a public health threat. While countries like England and Australia are nearing this goal, the United States is facing challenges in eradicating the disease, with approximately 11,000 deaths annually due to hepatitis C, a curable illness for the past decade.
Michigan, however, has made significant progress in reducing the burden of hepatitis C within the state. Dr. Natasha Bagdasarian, Michigan’s chief medical executive, highlighted the substantial decrease in chronic hepatitis C cases from around 10,000 in 2018 to slightly over 3,000 in 2022. This achievement is particularly commendable considering the insidious nature of the infection, where symptoms may not manifest for years, leading to undiagnosed cases.
Hepatitis C primarily spreads through direct contact with infected blood, such as needle-sharing during drug use, unsterile tattoo or piercing practices, accidental needle-sticks in healthcare settings, and vertical transmission from mother to child. To address this public health concern, Michigan launched the “We Treat Hep C” program in collaboration with various community organizations to enhance testing initiatives among high-risk populations.
A vital component of Michigan’s strategy involves ensuring access to effective treatment options like Mavyret, a medication known for curing hepatitis C with an eight-week regimen. Through negotiations, the state secured discounted prices for Mavyret, making it more affordable for individuals. While the out-of-pocket cost exceeds $16,000 without insurance, eligible Medicaid beneficiaries in Michigan can obtain the medication for a nominal co-pay of $1, while those enrolled in the Healthy Michigan Plan face no copay requirements.
Despite notable progress, challenges persist in the U.S. healthcare system, hindering comprehensive hepatitis C eradication efforts. Dr. Bagdasarian emphasized the importance of universal healthcare coverage in ensuring equitable access to detection and treatment services for all individuals, particularly those who may not qualify for Medicaid but lack affordable insurance alternatives. Addressing these systemic gaps is crucial for advancing the goal of making hepatitis C services universally available.
Recent data trends indicate continued improvement in Michigan’s fight against hepatitis C, with fewer than 2,000 new cases identified in 2025. This positive trajectory underscores the efficacy of targeted interventions and collaborative initiatives in combating the disease within the state.
